PE20131107A1 - Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina - Google Patents
Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-aminaInfo
- Publication number
- PE20131107A1 PE20131107A1 PE2013000192A PE2013000192A PE20131107A1 PE 20131107 A1 PE20131107 A1 PE 20131107A1 PE 2013000192 A PE2013000192 A PE 2013000192A PE 2013000192 A PE2013000192 A PE 2013000192A PE 20131107 A1 PE20131107 A1 PE 20131107A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- spyro
- pyrane
- cyclohexan
- indol
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- -1 POLYOXYETHYLENE Polymers 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
REFERIDA A UNA FORMA DE DOSIFICACION FARMACEUTICA PARA ADMINISTRACION ORAL QUE COMPRENDE UN MATERIAL DE MATRIZ POLIMERICO SOLIDO EN EL QUE SE DISPERSA EL AGENTE ACTIVO DE FORMULA (I), DONDE R ES H O CH3 Y EL POLIMERO ES POLIVINILPIRROLIDONA, COPOLIMEROS DE VINILPIRROLIDONA-ACETATO DE POLIVINILO, DERIVADOS DE CELULOSA, ENTRE OTROS. TAMBIEN COMPRENDE UN AGENTE TENSOACTIVO SELECCIONADO DE ESTERES DE ACIDO GRASO DE POLIOXIETILENO, ESTERES DE ACIDO GRASO PARCIAL DE POLIOXIETILENSORBITAN Y ESTERES DE ACIDO SULFURICO. SON COMPUESTOS FAVORITOS: (1r,4r)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA, (1r,4r)-6'-FLUORO-N-METIL-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA O UNA SAL DE LOS MISMOS. DICHA FORMA DE DOSIFICACION ES UTIL EN EL TRATAMIENTO DEL DOLOR AGUDO, VISCERAL, NEUROPATICO Y CRONICO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10008116 | 2010-08-04 | ||
| US201161370643P | 2011-08-04 | 2011-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20131107A1 true PE20131107A1 (es) | 2013-10-17 |
Family
ID=43481034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000192A PE20131107A1 (es) | 2010-08-04 | 2011-08-04 | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP2600839B1 (es) |
| JP (1) | JP5792300B2 (es) |
| KR (1) | KR101828768B1 (es) |
| CN (1) | CN103179953A (es) |
| AR (1) | AR082560A1 (es) |
| AU (1) | AU2011287956B2 (es) |
| BR (1) | BR112013002714A2 (es) |
| CA (1) | CA2804878C (es) |
| CL (1) | CL2012003582A1 (es) |
| CO (1) | CO6640315A2 (es) |
| CY (1) | CY1119887T1 (es) |
| DK (1) | DK2600839T3 (es) |
| EC (1) | ECSP13012419A (es) |
| ES (1) | ES2665344T3 (es) |
| HR (1) | HRP20180143T1 (es) |
| HU (1) | HUE035543T2 (es) |
| IL (1) | IL223880A (es) |
| LT (1) | LT2600839T (es) |
| MX (1) | MX345068B (es) |
| NZ (1) | NZ604735A (es) |
| PE (1) | PE20131107A1 (es) |
| PL (1) | PL2600839T3 (es) |
| PT (1) | PT2600839T (es) |
| RS (1) | RS57027B1 (es) |
| RU (1) | RU2582390C2 (es) |
| SI (1) | SI2600839T1 (es) |
| WO (1) | WO2012016699A2 (es) |
| ZA (1) | ZA201300038B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3247352B1 (en) | 2015-01-23 | 2020-06-24 | Grünenthal GmbH | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
| WO2017148595A1 (en) | 2016-02-29 | 2017-09-08 | Grünenthal GmbH | Titration of cebranopadol |
| WO2024129782A1 (en) | 2022-12-12 | 2024-06-20 | Park Therapeutics, Inc. | Regimens and compositions useful for alleviating pain |
| KR20250145673A (ko) | 2023-02-15 | 2025-10-13 | 애드뉴리스 테라퓨틱스 인코포레이티드 | 통증 완화에 유용한 요법 및 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| DE102007009235A1 (de) * | 2007-02-22 | 2008-09-18 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
-
2011
- 2011-08-04 DK DK11746175.6T patent/DK2600839T3/da active
- 2011-08-04 JP JP2013522137A patent/JP5792300B2/ja not_active Expired - Fee Related
- 2011-08-04 LT LTEP11746175.6T patent/LT2600839T/lt unknown
- 2011-08-04 PE PE2013000192A patent/PE20131107A1/es active IP Right Grant
- 2011-08-04 BR BR112013002714A patent/BR112013002714A2/pt not_active IP Right Cessation
- 2011-08-04 ES ES11746175.6T patent/ES2665344T3/es active Active
- 2011-08-04 RS RS20180336A patent/RS57027B1/sr unknown
- 2011-08-04 PT PT117461756T patent/PT2600839T/pt unknown
- 2011-08-04 KR KR1020137005272A patent/KR101828768B1/ko not_active Expired - Fee Related
- 2011-08-04 NZ NZ604735A patent/NZ604735A/en not_active IP Right Cessation
- 2011-08-04 AU AU2011287956A patent/AU2011287956B2/en not_active Ceased
- 2011-08-04 CN CN2011800382299A patent/CN103179953A/zh active Pending
- 2011-08-04 CA CA2804878A patent/CA2804878C/en not_active Expired - Fee Related
- 2011-08-04 SI SI201131434T patent/SI2600839T1/en unknown
- 2011-08-04 WO PCT/EP2011/003909 patent/WO2012016699A2/en not_active Ceased
- 2011-08-04 PL PL11746175T patent/PL2600839T3/pl unknown
- 2011-08-04 EP EP11746175.6A patent/EP2600839B1/en not_active Not-in-force
- 2011-08-04 RU RU2013109134/15A patent/RU2582390C2/ru not_active IP Right Cessation
- 2011-08-04 HR HRP20180143TT patent/HRP20180143T1/hr unknown
- 2011-08-04 HU HUE11746175A patent/HUE035543T2/en unknown
- 2011-08-04 MX MX2013001114A patent/MX345068B/es active IP Right Grant
- 2011-08-04 AR ARP110102820A patent/AR082560A1/es not_active Application Discontinuation
-
2012
- 2012-12-19 CL CL2012003582A patent/CL2012003582A1/es unknown
- 2012-12-19 CO CO12230427A patent/CO6640315A2/es not_active Application Discontinuation
- 2012-12-25 IL IL223880A patent/IL223880A/en active IP Right Grant
-
2013
- 2013-01-02 ZA ZA2013/00038A patent/ZA201300038B/en unknown
- 2013-02-04 EC ECSP13012419 patent/ECSP13012419A/es unknown
-
2018
- 2018-02-05 CY CY20181100142T patent/CY1119887T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20131108A1 (es) | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina | |
| PE20131084A1 (es) | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor nociceptivo | |
| PE20142353A1 (es) | Ansolvatos de sal de noribogaina | |
| ECSP14012527A (es) | Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre | |
| CO6571900A2 (es) | Composiciones famaceúticas del compuesto espiro-oxindol para adminsitración tópica y sus usos como agentes terapeúticos | |
| RU2013109138A (ru) | ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ-ИЛИ N,N-ДИМЕТИЛ-)-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН | |
| MX395136B (es) | Composiciones farmaceuticas y metodos de administracion relacionados. | |
| CU24350B1 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| AR070731A1 (es) | Composicion farmaceutica para farmacos poco solubles | |
| NI201400003A (es) | Una nueva composición terapéutica que contiene apomorfina como ingrediente activo | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| PE20131107A1 (es) | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina | |
| EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения | |
| PE20141113A1 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| CO6640318A2 (es) | Formas de dosificación oral de bendamustina | |
| UA109544C2 (uk) | Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення | |
| EA201170583A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
| AR093275A1 (es) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos | |
| EA201001000A1 (ru) | Антиоксидантное средство масляный бальзам "ювелакс" | |
| AR101227A1 (es) | Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor | |
| NI201200196A (es) | Agentes terapéuticos 976 | |
| EA201100682A1 (ru) | Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение | |
| EA201491404A1 (ru) | Системные лекарственные формы с контролируемым высвобождением и улучшенной стабильностью | |
| AR128434A2 (es) | Composiciones y métodos de absorción transmucosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |